The reports
Since 2025, users of GLP-1 receptor agonists, and more recently of the unapproved triple agonist retatrutide, have described emotional flattening, reduced libido and, in some accounts, anhedonia, the loss of the ability to feel pleasure. On 6 April 2026 The Guardian reported on a wave of videos in which users said retatrutide had blunted emotion and, in some accounts, affected relationships. These are patient reports, not trial outcomes. Retatrutide is not licensed in the UK or anywhere else.
What the circuitry research shows
GLP-1 receptors are enriched in brain regions central to reward processing, including the lateral septum, hypothalamus, amygdala, nucleus accumbens and ventral tegmental area, and GLP-1-producing neurons in the nucleus tractus solitarius project directly to the ventral tegmental area and nucleus accumbens. A 2026 systematic review by Dang and colleagues concluded that the hypothesis, that GLP-1 receptor agonists blunt neuroaffective responses to reward-related cues, is plausible and consistent with cross-domain findings on alcohol, nicotine and food, but that the studies so far are heterogeneous. It remains unresolved whether any blunting is specific to reward content or a generalised dampening of emotional reactivity.
A preclinical study from the Guler laboratory at the University of Virginia, published in Nature in 2026, mapped a circuit linking the hindbrain to the central amygdala and on to dopamine-producing neurons, and showed that newer oral GLP-1 drugs engage it, reducing not only hunger but the motivation to pursue rewarding food in the animal model. That is a mechanistic finding in mice. It is not evidence of an effect on human attachment.
What the evidence does not show
No randomised trial has measured anhedonia, libido or romantic attachment as an endpoint for any GLP-1 medicine. The user reports are uncontrolled: weight loss, rapid metabolic change, altered eating behaviour and pre-existing mood are all plausible confounders. Clinicians quoted in the reporting were explicit that the leap from reduced food cravings to an inability to fall in love is not supported by the current science.
The evidence grade for the reward-circuitry hypothesis is Limited: a coherent preclinical mechanism plus uncontrolled human reports, with no controlled human outcome data.
The UK position
None of the GLP-1 medicines licensed in the UK is authorised for any effect on mood, reward or attachment. Suspected adverse reactions to any medicine are reported to the MHRA through the Yellow Card scheme. Peptide Data describes research findings; it does not give consumption, dosing or self-administration advice, and all content is framed for research and educational use only.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.